All News

Cladribine (Mavenclad, EMD Serono) is the first oral multiple sclerosis drug to demonstrate 2 years of proven efficacy with a maximum of 20 days of treatment.

Study data suggest the drug helps reduce the risk of major adverse cardiovascular event in certain patients.

The goals are to assess the candidate’s safety and to determine if the vaccination induces the human immune system to produce proteins called neutralizing antibodies.

The National Rosacea Society (NRS) has designated April as Rosacea Awareness month to improve education of rosacea.

The combination therapy reduced the risk of squamous cell carcinoma development on the face and scalp by approximately 75% in the study.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care industry.

With this approval, certolizumab pegol becomes the first FDA-approved therapy for this type of axSpA, filling an unmet clinical need for treatment options, according to the release.

The action follows discontinuation of quinidine, the only FDA-approved intravenous antimalarial drug in the United States.

Certolizumab pegol (Cimzia) is the first FDA-approved therapy for this type of axial spondyloarthritis, filling an unmet clinical need for treatment options.

Aspirin and heroin were discovered within weeks of each other in 1897 by Felix Hoffmann.

ASHP’s Midyear Clinical Meeting rose 5 spots, from No. 157 to No. 152 out of 250 trade shows with the Consumer Electronics Shows (CES) topping the list.

Overall, more than half of commercially insured individuals who initiated pre-exposure prophylaxis persisted with it for the 12-month duration of the cohort study.

An updated transmission model indicates that most new HIV infections occur due to a lack of diagnosis and treatment.

Top news of the day from across the health care industry.